The global Cell-Free Circulating Tumor DNA (ctDNA) market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.

North American market for Cell-Free Circulating Tumor DNA (ctDNA) is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.

Asia-Pacific market for Cell-Free Circulating Tumor DNA (ctDNA) is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.

The global market for Cell-Free Circulating Tumor DNA (ctDNA) in Hospital is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.

The major global companies of Cell-Free Circulating Tumor DNA (ctDNA) include Nexomics, Roche, ORIOMICS, Signatera, Illumina, Sysmex Corporation, Bio-Rad, Biocartis and QIAGEN, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.

This report aims to provide a comprehensive presentation of the global market for Cell-Free Circulating Tumor DNA (ctDNA), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Cell-Free Circulating Tumor DNA (ctDNA).

Report Scope

The Cell-Free Circulating Tumor DNA (ctDNA) market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Cell-Free Circulating Tumor DNA (ctDNA) market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Cell-Free Circulating Tumor DNA (ctDNA) companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of Cell-Free Circulating Tumor DNA (ctDNA) Market Report

Report Metric	Details
Report Name	Cell-Free Circulating Tumor DNA (ctDNA) Market
Segment by Type	Gastric Cancer Methylation Screening Esophageal Cancer Methylation Screening Colorectal Cancer Methylation Screening Lung Cancer Methylation Screening Liver Cancer Methylation Screening Other Cancer Screening
Segment by Application	Hospital Medical Center Laboratory
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Nexomics, Roche, ORIOMICS, Signatera, Illumina, Sysmex Corporation, Bio-Rad, Biocartis, QIAGEN, GuardantHealth, GSK plc, AstraZeneca, NeoGenomics Laboratories, AmoyDx, Annoroad, Burning Rock Biotech
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Cell-Free Circulating Tumor DNA (ctDNA) companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the Cell-Free Circulating Tumor DNA (ctDNA) Market report?

Ans: The main players in the Cell-Free Circulating Tumor DNA (ctDNA) Market are Nexomics, Roche, ORIOMICS, Signatera, Illumina, Sysmex Corporation, Bio-Rad, Biocartis, QIAGEN, GuardantHealth, GSK plc, AstraZeneca, NeoGenomics Laboratories, AmoyDx, Annoroad, Burning Rock Biotech

What are the Application segmentation covered in the Cell-Free Circulating Tumor DNA (ctDNA) Market report?

Ans: The Applications covered in the Cell-Free Circulating Tumor DNA (ctDNA) Market report are Hospital, Medical Center, Laboratory

What are the Type segmentation covered in the Cell-Free Circulating Tumor DNA (ctDNA) Market report?

Ans: The Types covered in the Cell-Free Circulating Tumor DNA (ctDNA) Market report are Gastric Cancer Methylation Screening, Esophageal Cancer Methylation Screening, Colorectal Cancer Methylation Screening, Lung Cancer Methylation Screening, Liver Cancer Methylation Screening, Other Cancer Screening

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size Growth Rate by Type: 2019 VS 2023 VS 2030

1.2.2 Gastric Cancer Methylation Screening

1.2.3 Esophageal Cancer Methylation Screening

1.2.4 Colorectal Cancer Methylation Screening

1.2.5 Lung Cancer Methylation Screening

1.2.6 Liver Cancer Methylation Screening

1.2.7 Other Cancer Screening

1.3 Market by Application

1.3.1 Global Cell-Free Circulating Tumor DNA (ctDNA) Market Growth by Application: 2019 VS 2023 VS 2030

1.3.2 Hospital

1.3.3 Medical Center

1.3.4 Laboratory

1.4 Study Objectives

1.5 Years Considered

1.6 Years Considered

2 Global Growth Trends

2.1 Global Cell-Free Circulating Tumor DNA (ctDNA) Market Perspective (2019-2030)

2.2 Cell-Free Circulating Tumor DNA (ctDNA) Growth Trends by Region

2.2.1 Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Region: 2019 VS 2023 VS 2030

2.2.2 Cell-Free Circulating Tumor DNA (ctDNA) Historic Market Size by Region (2019-2024)

2.2.3 Cell-Free Circulating Tumor DNA (ctDNA) Forecasted Market Size by Region (2025-2030)

2.3 Cell-Free Circulating Tumor DNA (ctDNA) Market Dynamics

2.3.1 Cell-Free Circulating Tumor DNA (ctDNA) Industry Trends

2.3.2 Cell-Free Circulating Tumor DNA (ctDNA) Market Drivers

2.3.3 Cell-Free Circulating Tumor DNA (ctDNA) Market Challenges

2.3.4 Cell-Free Circulating Tumor DNA (ctDNA) Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Cell-Free Circulating Tumor DNA (ctDNA) Players by Revenue

3.1.1 Global Top Cell-Free Circulating Tumor DNA (ctDNA) Players by Revenue (2019-2024)

3.1.2 Global Cell-Free Circulating Tumor DNA (ctDNA) Revenue Market Share by Players (2019-2024)

3.2 Global Cell-Free Circulating Tumor DNA (ctDNA) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Players Covered: Ranking by Cell-Free Circulating Tumor DNA (ctDNA) Revenue

3.4 Global Cell-Free Circulating Tumor DNA (ctDNA) Market Concentration Ratio

3.4.1 Global Cell-Free Circulating Tumor DNA (ctDNA) Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Cell-Free Circulating Tumor DNA (ctDNA) Revenue in 2023

3.5 Cell-Free Circulating Tumor DNA (ctDNA) Key Players Head office and Area Served

3.6 Key Players Cell-Free Circulating Tumor DNA (ctDNA) Product Solution and Service

3.7 Date of Enter into Cell-Free Circulating Tumor DNA (ctDNA) Market

3.8 Mergers & Acquisitions, Expansion Plans

4 Cell-Free Circulating Tumor DNA (ctDNA) Breakdown Data by Type

4.1 Global Cell-Free Circulating Tumor DNA (ctDNA) Historic Market Size by Type (2019-2024)

4.2 Global Cell-Free Circulating Tumor DNA (ctDNA) Forecasted Market Size by Type (2025-2030)

5 Cell-Free Circulating Tumor DNA (ctDNA) Breakdown Data by Application

5.1 Global Cell-Free Circulating Tumor DNA (ctDNA) Historic Market Size by Application (2019-2024)

5.2 Global Cell-Free Circulating Tumor DNA (ctDNA) Forecasted Market Size by Application (2025-2030)

6 North America

6.1 North America Cell-Free Circulating Tumor DNA (ctDNA) Market Size (2019-2030)

6.2 North America Cell-Free Circulating Tumor DNA (ctDNA) Market Growth Rate by Country: 2019 VS 2023 VS 2030

6.3 North America Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Country (2019-2024)

6.4 North America Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Country (2025-2030)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Cell-Free Circulating Tumor DNA (ctDNA) Market Size (2019-2030)

7.2 Europe Cell-Free Circulating Tumor DNA (ctDNA) Market Growth Rate by Country: 2019 VS 2023 VS 2030

7.3 Europe Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Country (2019-2024)

7.4 Europe Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Country (2025-2030)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8 Asia-Pacific

8.1 Asia-Pacific Cell-Free Circulating Tumor DNA (ctDNA) Market Size (2019-2030)

8.2 Asia-Pacific Cell-Free Circulating Tumor DNA (ctDNA) Market Growth Rate by Region: 2019 VS 2023 VS 2030

8.3 Asia-Pacific Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Region (2019-2024)

8.4 Asia-Pacific Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Region (2025-2030)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9 Latin America

9.1 Latin America Cell-Free Circulating Tumor DNA (ctDNA) Market Size (2019-2030)

9.2 Latin America Cell-Free Circulating Tumor DNA (ctDNA) Market Growth Rate by Country: 2019 VS 2023 VS 2030

9.3 Latin America Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Country (2019-2024)

9.4 Latin America Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Country (2025-2030)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Cell-Free Circulating Tumor DNA (ctDNA) Market Size (2019-2030)

10.2 Middle East & Africa Cell-Free Circulating Tumor DNA (ctDNA) Market Growth Rate by Country: 2019 VS 2023 VS 2030

10.3 Middle East & Africa Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Country (2019-2024)

10.4 Middle East & Africa Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Country (2025-2030)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Nexomics

11.1.1 Nexomics Company Detail

11.1.2 Nexomics Business Overview

11.1.3 Nexomics Cell-Free Circulating Tumor DNA (ctDNA) Introduction

11.1.4 Nexomics Revenue in Cell-Free Circulating Tumor DNA (ctDNA) Business (2019-2024)

11.1.5 Nexomics Recent Development

11.2 Roche

11.2.1 Roche Company Detail

11.2.2 Roche Business Overview

11.2.3 Roche Cell-Free Circulating Tumor DNA (ctDNA) Introduction

11.2.4 Roche Revenue in Cell-Free Circulating Tumor DNA (ctDNA) Business (2019-2024)

11.2.5 Roche Recent Development

11.3 ORIOMICS

11.3.1 ORIOMICS Company Detail

11.3.2 ORIOMICS Business Overview

11.3.3 ORIOMICS Cell-Free Circulating Tumor DNA (ctDNA) Introduction

11.3.4 ORIOMICS Revenue in Cell-Free Circulating Tumor DNA (ctDNA) Business (2019-2024)

11.3.5 ORIOMICS Recent Development

11.4 Signatera

11.4.1 Signatera Company Detail

11.4.2 Signatera Business Overview

11.4.3 Signatera Cell-Free Circulating Tumor DNA (ctDNA) Introduction

11.4.4 Signatera Revenue in Cell-Free Circulating Tumor DNA (ctDNA) Business (2019-2024)

11.4.5 Signatera Recent Development

11.5 Illumina

11.5.1 Illumina Company Detail

11.5.2 Illumina Business Overview

11.5.3 Illumina Cell-Free Circulating Tumor DNA (ctDNA) Introduction

11.5.4 Illumina Revenue in Cell-Free Circulating Tumor DNA (ctDNA) Business (2019-2024)

11.5.5 Illumina Recent Development

11.6 Sysmex Corporation

11.6.1 Sysmex Corporation Company Detail

11.6.2 Sysmex Corporation Business Overview

11.6.3 Sysmex Corporation Cell-Free Circulating Tumor DNA (ctDNA) Introduction

11.6.4 Sysmex Corporation Revenue in Cell-Free Circulating Tumor DNA (ctDNA) Business (2019-2024)

11.6.5 Sysmex Corporation Recent Development

11.7 Bio-Rad

11.7.1 Bio-Rad Company Detail

11.7.2 Bio-Rad Business Overview

11.7.3 Bio-Rad Cell-Free Circulating Tumor DNA (ctDNA) Introduction

11.7.4 Bio-Rad Revenue in Cell-Free Circulating Tumor DNA (ctDNA) Business (2019-2024)

11.7.5 Bio-Rad Recent Development

11.8 Biocartis

11.8.1 Biocartis Company Detail

11.8.2 Biocartis Business Overview

11.8.3 Biocartis Cell-Free Circulating Tumor DNA (ctDNA) Introduction

11.8.4 Biocartis Revenue in Cell-Free Circulating Tumor DNA (ctDNA) Business (2019-2024)

11.8.5 Biocartis Recent Development

11.9 QIAGEN

11.9.1 QIAGEN Company Detail

11.9.2 QIAGEN Business Overview

11.9.3 QIAGEN Cell-Free Circulating Tumor DNA (ctDNA) Introduction

11.9.4 QIAGEN Revenue in Cell-Free Circulating Tumor DNA (ctDNA) Business (2019-2024)

11.9.5 QIAGEN Recent Development

11.10 GuardantHealth

11.10.1 GuardantHealth Company Detail

11.10.2 GuardantHealth Business Overview

11.10.3 GuardantHealth Cell-Free Circulating Tumor DNA (ctDNA) Introduction

11.10.4 GuardantHealth Revenue in Cell-Free Circulating Tumor DNA (ctDNA) Business (2019-2024)

11.10.5 GuardantHealth Recent Development

11.11 GSK plc

11.11.1 GSK plc Company Detail

11.11.2 GSK plc Business Overview

11.11.3 GSK plc Cell-Free Circulating Tumor DNA (ctDNA) Introduction

11.11.4 GSK plc Revenue in Cell-Free Circulating Tumor DNA (ctDNA) Business (2019-2024)

11.11.5 GSK plc Recent Development

11.12 AstraZeneca

11.12.1 AstraZeneca Company Detail

11.12.2 AstraZeneca Business Overview

11.12.3 AstraZeneca Cell-Free Circulating Tumor DNA (ctDNA) Introduction

11.12.4 AstraZeneca Revenue in Cell-Free Circulating Tumor DNA (ctDNA) Business (2019-2024)

11.12.5 AstraZeneca Recent Development

11.13 NeoGenomics Laboratories

11.13.1 NeoGenomics Laboratories Company Detail

11.13.2 NeoGenomics Laboratories Business Overview

11.13.3 NeoGenomics Laboratories Cell-Free Circulating Tumor DNA (ctDNA) Introduction

11.13.4 NeoGenomics Laboratories Revenue in Cell-Free Circulating Tumor DNA (ctDNA) Business (2019-2024)

11.13.5 NeoGenomics Laboratories Recent Development

11.14 AmoyDx

11.14.1 AmoyDx Company Detail

11.14.2 AmoyDx Business Overview

11.14.3 AmoyDx Cell-Free Circulating Tumor DNA (ctDNA) Introduction

11.14.4 AmoyDx Revenue in Cell-Free Circulating Tumor DNA (ctDNA) Business (2019-2024)

11.14.5 AmoyDx Recent Development

11.15 Annoroad

11.15.1 Annoroad Company Detail

11.15.2 Annoroad Business Overview

11.15.3 Annoroad Cell-Free Circulating Tumor DNA (ctDNA) Introduction

11.15.4 Annoroad Revenue in Cell-Free Circulating Tumor DNA (ctDNA) Business (2019-2024)

11.15.5 Annoroad Recent Development

11.16 Burning Rock Biotech

11.16.1 Burning Rock Biotech Company Detail

11.16.2 Burning Rock Biotech Business Overview

11.16.3 Burning Rock Biotech Cell-Free Circulating Tumor DNA (ctDNA) Introduction

11.16.4 Burning Rock Biotech Revenue in Cell-Free Circulating Tumor DNA (ctDNA) Business (2019-2024)

11.16.5 Burning Rock Biotech Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.2 Data Source

13.2 Disclaimer

13.3 Author Details

FEATURED COMPANIES

Neogenomics Laboratories

Amoydx

Annoroad

Burning Rock Biotech

List of Tables

Table 1. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030

Table 2. Key Players of Gastric Cancer Methylation Screening

Table 3. Key Players of Esophageal Cancer Methylation Screening

Table 4. Key Players of Colorectal Cancer Methylation Screening

Table 5. Key Players of Lung Cancer Methylation Screening

Table 6. Key Players of Liver Cancer Methylation Screening

Table 7. Key Players of Other Cancer Screening

Table 8. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030

Table 9. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Region (US$ Million): 2019 VS 2023 VS 2030

Table 10. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Region (2019-2024) & (US$ Million)

Table 11. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Share by Region (2019-2024)

Table 12. Global Cell-Free Circulating Tumor DNA (ctDNA) Forecasted Market Size by Region (2025-2030) & (US$ Million)

Table 13. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Share by Region (2025-2030)

Table 14. Cell-Free Circulating Tumor DNA (ctDNA) Market Trends

Table 15. Cell-Free Circulating Tumor DNA (ctDNA) Market Drivers

Table 16. Cell-Free Circulating Tumor DNA (ctDNA) Market Challenges

Table 17. Cell-Free Circulating Tumor DNA (ctDNA) Market Restraints

Table 18. Global Cell-Free Circulating Tumor DNA (ctDNA) Revenue by Players (2019-2024) & (US$ Million)

Table 19. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Share by Players (2019-2024)

Table 20. Global Top Cell-Free Circulating Tumor DNA (ctDNA) Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Cell-Free Circulating Tumor DNA (ctDNA) as of 2023)

Table 21. Ranking of Global Top Cell-Free Circulating Tumor DNA (ctDNA) Companies by Revenue (US$ Million) in 2023

Table 22. Global 5 Largest Players Market Share by Cell-Free Circulating Tumor DNA (ctDNA) Revenue (CR5 and HHI) & (2019-2024)

Table 23. Key Players Headquarters and Area Served

Table 24. Key Players Cell-Free Circulating Tumor DNA (ctDNA) Product Solution and Service

Table 25. Date of Enter into Cell-Free Circulating Tumor DNA (ctDNA) Market

Table 26. Mergers & Acquisitions, Expansion Plans

Table 27. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Type (2019-2024) & (US$ Million)

Table 28. Global Cell-Free Circulating Tumor DNA (ctDNA) Revenue Market Share by Type (2019-2024)

Table 29. Global Cell-Free Circulating Tumor DNA (ctDNA) Forecasted Market Size by Type (2025-2030) & (US$ Million)

Table 30. Global Cell-Free Circulating Tumor DNA (ctDNA) Revenue Market Share by Type (2025-2030)

Table 31. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Application (2019-2024) & (US$ Million)

Table 32. Global Cell-Free Circulating Tumor DNA (ctDNA) Revenue Market Share by Application (2019-2024)

Table 33. Global Cell-Free Circulating Tumor DNA (ctDNA) Forecasted Market Size by Application (2025-2030) & (US$ Million)

Table 34. Global Cell-Free Circulating Tumor DNA (ctDNA) Revenue Market Share by Application (2025-2030)

Table 35. North America Cell-Free Circulating Tumor DNA (ctDNA) Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 36. North America Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Country (2019-2024) & (US$ Million)

Table 37. North America Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Country (2025-2030) & (US$ Million)

Table 38. Europe Cell-Free Circulating Tumor DNA (ctDNA) Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 39. Europe Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Country (2019-2024) & (US$ Million)

Table 40. Europe Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Country (2025-2030) & (US$ Million)

Table 41. Asia-Pacific Cell-Free Circulating Tumor DNA (ctDNA) Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030

Table 42. Asia-Pacific Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Region (2019-2024) & (US$ Million)

Table 43. Asia-Pacific Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Region (2025-2030) & (US$ Million)

Table 44. Latin America Cell-Free Circulating Tumor DNA (ctDNA) Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 45. Latin America Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Country (2019-2024) & (US$ Million)

Table 46. Latin America Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Country (2025-2030) & (US$ Million)

Table 47. Middle East & Africa Cell-Free Circulating Tumor DNA (ctDNA) Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 48. Middle East & Africa Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Country (2019-2024) & (US$ Million)

Table 49. Middle East & Africa Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Country (2025-2030) & (US$ Million)

Table 50. Nexomics Company Detail

Table 51. Nexomics Business Overview

Table 52. Nexomics Cell-Free Circulating Tumor DNA (ctDNA) Product

Table 53. Nexomics Revenue in Cell-Free Circulating Tumor DNA (ctDNA) Business (2019-2024) & (US$ Million)

Table 54. Nexomics Recent Development

Table 55. Roche Company Detail

Table 56. Roche Business Overview

Table 57. Roche Cell-Free Circulating Tumor DNA (ctDNA) Product

Table 58. Roche Revenue in Cell-Free Circulating Tumor DNA (ctDNA) Business (2019-2024) & (US$ Million)

Table 59. Roche Recent Development

Table 60. ORIOMICS Company Detail

Table 61. ORIOMICS Business Overview

Table 62. ORIOMICS Cell-Free Circulating Tumor DNA (ctDNA) Product

Table 63. ORIOMICS Revenue in Cell-Free Circulating Tumor DNA (ctDNA) Business (2019-2024) & (US$ Million)

Table 64. ORIOMICS Recent Development

Table 65. Signatera Company Detail

Table 66. Signatera Business Overview

Table 67. Signatera Cell-Free Circulating Tumor DNA (ctDNA) Product

Table 68. Signatera Revenue in Cell-Free Circulating Tumor DNA (ctDNA) Business (2019-2024) & (US$ Million)

Table 69. Signatera Recent Development

Table 70. Illumina Company Detail

Table 71. Illumina Business Overview

Table 72. Illumina Cell-Free Circulating Tumor DNA (ctDNA) Product

Table 73. Illumina Revenue in Cell-Free Circulating Tumor DNA (ctDNA) Business (2019-2024) & (US$ Million)

Table 74. Illumina Recent Development

Table 75. Sysmex Corporation Company Detail

Table 76. Sysmex Corporation Business Overview

Table 77. Sysmex Corporation Cell-Free Circulating Tumor DNA (ctDNA) Product

Table 78. Sysmex Corporation Revenue in Cell-Free Circulating Tumor DNA (ctDNA) Business (2019-2024) & (US$ Million)

Table 79. Sysmex Corporation Recent Development

Table 80. Bio-Rad Company Detail

Table 81. Bio-Rad Business Overview

Table 82. Bio-Rad Cell-Free Circulating Tumor DNA (ctDNA) Product

Table 83. Bio-Rad Revenue in Cell-Free Circulating Tumor DNA (ctDNA) Business (2019-2024) & (US$ Million)

Table 84. Bio-Rad Recent Development

Table 85. Biocartis Company Detail

Table 86. Biocartis Business Overview

Table 87. Biocartis Cell-Free Circulating Tumor DNA (ctDNA) Product

Table 88. Biocartis Revenue in Cell-Free Circulating Tumor DNA (ctDNA) Business (2019-2024) & (US$ Million)

Table 89. Biocartis Recent Development

Table 90. QIAGEN Company Detail

Table 91. QIAGEN Business Overview

Table 92. QIAGEN Cell-Free Circulating Tumor DNA (ctDNA) Product

Table 93. QIAGEN Revenue in Cell-Free Circulating Tumor DNA (ctDNA) Business (2019-2024) & (US$ Million)

Table 94. QIAGEN Recent Development

Table 95. GuardantHealth Company Detail

Table 96. GuardantHealth Business Overview

Table 97. GuardantHealth Cell-Free Circulating Tumor DNA (ctDNA) Product

Table 98. GuardantHealth Revenue in Cell-Free Circulating Tumor DNA (ctDNA) Business (2019-2024) & (US$ Million)

Table 99. GuardantHealth Recent Development

Table 100. GSK plc Company Detail

Table 101. GSK plc Business Overview

Table 102. GSK plc Cell-Free Circulating Tumor DNA (ctDNA) Product

Table 103. GSK plc Revenue in Cell-Free Circulating Tumor DNA (ctDNA) Business (2019-2024) & (US$ Million)

Table 104. GSK plc Recent Development

Table 105. AstraZeneca Company Detail

Table 106. AstraZeneca Business Overview

Table 107. AstraZeneca Cell-Free Circulating Tumor DNA (ctDNA) Product

Table 108. AstraZeneca Revenue in Cell-Free Circulating Tumor DNA (ctDNA) Business (2019-2024) & (US$ Million)

Table 109. AstraZeneca Recent Development

Table 110. NeoGenomics Laboratories Company Detail

Table 111. NeoGenomics Laboratories Business Overview

Table 112. NeoGenomics Laboratories Cell-Free Circulating Tumor DNA (ctDNA) Product

Table 113. NeoGenomics Laboratories Revenue in Cell-Free Circulating Tumor DNA (ctDNA) Business (2019-2024) & (US$ Million)

Table 114. NeoGenomics Laboratories Recent Development

Table 115. AmoyDx Company Detail

Table 116. AmoyDx Business Overview

Table 117. AmoyDx Cell-Free Circulating Tumor DNA (ctDNA) Product

Table 118. AmoyDx Revenue in Cell-Free Circulating Tumor DNA (ctDNA) Business (2019-2024) & (US$ Million)

Table 119. AmoyDx Recent Development

Table 120. Annoroad Company Detail

Table 121. Annoroad Business Overview

Table 122. Annoroad Cell-Free Circulating Tumor DNA (ctDNA) Product

Table 123. Annoroad Revenue in Cell-Free Circulating Tumor DNA (ctDNA) Business (2019-2024) & (US$ Million)

Table 124. Annoroad Recent Development

Table 125. Burning Rock Biotech Company Detail

Table 126. Burning Rock Biotech Business Overview

Table 127. Burning Rock Biotech Cell-Free Circulating Tumor DNA (ctDNA) Product

Table 128. Burning Rock Biotech Revenue in Cell-Free Circulating Tumor DNA (ctDNA) Business (2019-2024) & (US$ Million)

Table 129. Burning Rock Biotech Recent Development

Table 130. Research Programs/Design for This Report

Table 131. Key Data Information from Secondary Sources

Table 132. Key Data Information from Primary Sources

List of Figures

Figure 1. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size Comparison by Type (2024-2030) & (US$ Million)

Figure 2. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Share by Type: 2023 VS 2030

Figure 3. Gastric Cancer Methylation Screening Features

Figure 4. Esophageal Cancer Methylation Screening Features

Figure 5. Colorectal Cancer Methylation Screening Features

Figure 6. Lung Cancer Methylation Screening Features

Figure 7. Liver Cancer Methylation Screening Features

Figure 8. Other Cancer Screening Features

Figure 9. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size Comparison by Application (2024-2030) & (US$ Million)

Figure 10. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Share by Application: 2023 VS 2030

Figure 11. Hospital Case Studies

Figure 12. Medical Center Case Studies

Figure 13. Laboratory Case Studies

Figure 14. Cell-Free Circulating Tumor DNA (ctDNA) Report Years Considered

Figure 15. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size (US$ Million), Year-over-Year: 2019-2030

Figure 16. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size, (US$ Million), 2019 VS 2023 VS 2030

Figure 17. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Share by Region: 2023 VS 2030

Figure 18. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Share by Players in 2023

Figure 19. Global Top Cell-Free Circulating Tumor DNA (ctDNA) Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Cell-Free Circulating Tumor DNA (ctDNA) as of 2023)

Figure 20. The Top 10 and 5 Players Market Share by Cell-Free Circulating Tumor DNA (ctDNA) Revenue in 2023

Figure 21. North America Cell-Free Circulating Tumor DNA (ctDNA) Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 22. North America Cell-Free Circulating Tumor DNA (ctDNA) Market Share by Country (2019-2030)

Figure 23. United States Cell-Free Circulating Tumor DNA (ctDNA) Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 24. Canada Cell-Free Circulating Tumor DNA (ctDNA) Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 25. Europe Cell-Free Circulating Tumor DNA (ctDNA) Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 26. Europe Cell-Free Circulating Tumor DNA (ctDNA) Market Share by Country (2019-2030)

Figure 27. Germany Cell-Free Circulating Tumor DNA (ctDNA) Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 28. France Cell-Free Circulating Tumor DNA (ctDNA) Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 29. U.K. Cell-Free Circulating Tumor DNA (ctDNA) Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 30. Italy Cell-Free Circulating Tumor DNA (ctDNA) Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 31. Russia Cell-Free Circulating Tumor DNA (ctDNA) Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 32. Nordic Countries Cell-Free Circulating Tumor DNA (ctDNA) Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 33. Asia-Pacific Cell-Free Circulating Tumor DNA (ctDNA) Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 34. Asia-Pacific Cell-Free Circulating Tumor DNA (ctDNA) Market Share by Region (2019-2030)

Figure 35. China Cell-Free Circulating Tumor DNA (ctDNA) Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 36. Japan Cell-Free Circulating Tumor DNA (ctDNA) Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 37. South Korea Cell-Free Circulating Tumor DNA (ctDNA) Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 38. Southeast Asia Cell-Free Circulating Tumor DNA (ctDNA) Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 39. India Cell-Free Circulating Tumor DNA (ctDNA) Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 40. Australia Cell-Free Circulating Tumor DNA (ctDNA) Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 41. Latin America Cell-Free Circulating Tumor DNA (ctDNA) Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 42. Latin America Cell-Free Circulating Tumor DNA (ctDNA) Market Share by Country (2019-2030)

Figure 43. Mexico Cell-Free Circulating Tumor DNA (ctDNA) Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 44. Brazil Cell-Free Circulating Tumor DNA (ctDNA) Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 45. Middle East & Africa Cell-Free Circulating Tumor DNA (ctDNA) Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 46. Middle East & Africa Cell-Free Circulating Tumor DNA (ctDNA) Market Share by Country (2019-2030)

Figure 47. Turkey Cell-Free Circulating Tumor DNA (ctDNA) Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 48. Saudi Arabia Cell-Free Circulating Tumor DNA (ctDNA) Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 49. Nexomics Revenue Growth Rate in Cell-Free Circulating Tumor DNA (ctDNA) Business (2019-2024)

Figure 50. Roche Revenue Growth Rate in Cell-Free Circulating Tumor DNA (ctDNA) Business (2019-2024)

Figure 51. ORIOMICS Revenue Growth Rate in Cell-Free Circulating Tumor DNA (ctDNA) Business (2019-2024)

Figure 52. Signatera Revenue Growth Rate in Cell-Free Circulating Tumor DNA (ctDNA) Business (2019-2024)

Figure 53. Illumina Revenue Growth Rate in Cell-Free Circulating Tumor DNA (ctDNA) Business (2019-2024)

Figure 54. Sysmex Corporation Revenue Growth Rate in Cell-Free Circulating Tumor DNA (ctDNA) Business (2019-2024)

Figure 55. Bio-Rad Revenue Growth Rate in Cell-Free Circulating Tumor DNA (ctDNA) Business (2019-2024)

Figure 56. Biocartis Revenue Growth Rate in Cell-Free Circulating Tumor DNA (ctDNA) Business (2019-2024)

Figure 57. QIAGEN Revenue Growth Rate in Cell-Free Circulating Tumor DNA (ctDNA) Business (2019-2024)

Figure 58. GuardantHealth Revenue Growth Rate in Cell-Free Circulating Tumor DNA (ctDNA) Business (2019-2024)

Figure 59. GSK plc Revenue Growth Rate in Cell-Free Circulating Tumor DNA (ctDNA) Business (2019-2024)

Figure 60. AstraZeneca Revenue Growth Rate in Cell-Free Circulating Tumor DNA (ctDNA) Business (2019-2024)

Figure 61. NeoGenomics Laboratories Revenue Growth Rate in Cell-Free Circulating Tumor DNA (ctDNA) Business (2019-2024)

Figure 62. AmoyDx Revenue Growth Rate in Cell-Free Circulating Tumor DNA (ctDNA) Business (2019-2024)

Figure 63. Annoroad Revenue Growth Rate in Cell-Free Circulating Tumor DNA (ctDNA) Business (2019-2024)

Figure 64. Burning Rock Biotech Revenue Growth Rate in Cell-Free Circulating Tumor DNA (ctDNA) Business (2019-2024)

Figure 65. Bottom-up and Top-down Approaches for This Report

Figure 66. Data Triangulation

Figure 67. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

120 Pages

Type: Report

Code: QYRE-Auto-5V5924

Mon Oct 07 00:00:00 UTC 2024

Add to Cart

Transarterial Chemoembolization (TACE) - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

120 Pages

Type: Report

Code: QYRE-Auto-18Y13983

Mon Oct 07 00:00:00 UTC 2024

Add to Cart

Multiple Myeloma Drugs - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

120 Pages

Type: Report

Code: QYRE-Auto-37R6886

Mon Oct 07 00:00:00 UTC 2024

Add to Cart

Global Heavy Ion Radiotherapy Market Research Report 2024

120 Pages

Type: Report

Code: QYRE-Auto-9J14338

Sun Oct 06 00:00:00 UTC 2024

Add to Cart

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions

Global Cell-Free Circulating Tumor DNA (ctDNA) Market Research Report 2024

Published Date: August 2024

Report Code: QYRE-Auto-2W15676

Global Cell-Free Circulating Tumor DNA (ctDNA) Market Research Report 2024

FEATURED COMPANIES

Cell-Free Circulating Tumor DNA (ctDNA) Market

Report Scope

Scope of Cell-Free Circulating Tumor DNA (ctDNA) Market Report

Chapter Outline

FAQ for this report

Who are the main players in the Cell-Free Circulating Tumor DNA (ctDNA) Market report?

What are the Application segmentation covered in the Cell-Free Circulating Tumor DNA (ctDNA) Market report?

What are the Type segmentation covered in the Cell-Free Circulating Tumor DNA (ctDNA) Market report?

FEATURED COMPANIES

RELATED REPORTS